Category: Media Outreach

Posted on

Bertelsmann Stiftung BTI Survey 2026: More Autocracies Worldwide – But Democratic Resistance Is Growing

Source: Media Outreach

Democracy is on the defensive. This is shown by the Bertelsmann Stiftung’s Transformation Index 2026 (BTI). The BTI was first surveyed twenty years ago, when democracies were still in the majority. Today, 56 percent of the 137 countries surveyed by the BTI are ruled autocratically. However, this rarely leads to better governance. Autocracies are more susceptible to corruption, less capable of shaping the future, and less consensus-oriented. However, examples such as Poland and Brazil show that social resistance and political competition can pave the way back to democracy.

GÜTERSLOH, GERMANY – Newsaktuell – 26 March 2026 – A majority of 77 of the 137 states surveyed by the BTI are now ruled autocratically and are taking increasingly repressive action against the opposition, the media and civil society. Of these countries, 52 are hard-line autocracies in which fundamental rights are completely disregarded – more than at any time since the survey began in 2006. But autocratic tendencies are also gaining ground in numerous democracies. “Many elected governments have undermined core democratic institutions in order to stay in power, and this paves the way for autocracy,” says democracy expert Sabine Donner.

In 54 percent of the countries, elections no longer meet minimum standards. In some countries, such as Gabon or Niger, they were suspended after military coups, while in Belarus, Russia and Rwanda they are strictly controlled legitimizating rituals. However, numerous free and fair elections also led to peaceful changes of government. In Madagascar, Tanzania and Venezuela, mass protests following rigged elections were violently suppressed, but strengthened political mobilization beyond the election date.

Examples such as El Salvador, Serbia and Turkey show that the repeatedly touted promise of authoritarian efficiency is rarely fulfilled. Corruption is insufficiently combated in more than 100 countries, two thirds of which are autocracies. “In autocracies, loyalty must be rewarded and positions secured,” says BTI expert Hauke Hartmann. “The supposed efficiency of authoritarian regimes is a myth.”

However, persistent grievances continue to ensure that protests by dissatisfied citizens show no sign of abating. In Bangladesh, Nepal and Sri Lanka, protests forced a democratic opening, while a democratic turnaround was achieved in Brazil and Poland. “The BTI shows how much pressure democratic institutions are coming under – at the same time, we are seeing remarkably lively resistance to their erosion in many places,” says Daniela Schwarzer, Member of the Executive Board, Bertelsmann Stiftung. “This ability to mobilize, which comes above all from an active civil society, is a key potential for democratic renewal.”

www.bti-project.org

Additional information:
 Since 2006, the Bertelsmann Stiftung’s Transformation Index has analyzed the quality of democracy, market economy and governance in 137 countries every two years. Currently, 23 OECD countries, such as Germany and the USA, are not part of the study. The study was carried out between February 1, 2023 and January 31, 2025.

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/bertelsmann-stiftung-bti-survey-2026-more-autocracies-worldwide-but-democratic-resistance-is-growing/

Posted on

2026 Ningbo Image Overseas Exhibition Concludes Successfully in Hong Kong, China

Source: Media Outreach

HONG KONG SAR – Media OutReach Newswire – 26 March 2026 – On the afternoon of 21 March, the 2026 Ningbo Image Overseas Exhibition took place at the Hong Kong CineArt MegaBox. Using visual media as a connecting thread, the event built a bridge for cultural exchange between Ningbo and Hong Kong, allowing Hong Kong audiences to experience the charm of Ningbo up close.

The event comprised three components: a Ningbo-themed film screening, a creative salon, and the ‘Experience Ningbo’ city exhibition, attracting enthusiastic participation from staff and students of Hong Kong Baptist University, as well as local cultural figures.

The Ningbo-themed film screening presented three films from Ningbo and five short films from the 30°Ningbo Short Film Festival, showcasing Ningbo’s cultural heritage and natural scenery through the lens.

The creative salon invited three guests—director Jiang Xiaoxuan, Hong Kong Baptist University lecturer Lai Kin-fung, and Southern Film Company Limited‌ Manager Lin Yunhua—to explore new avenues for the visual dissemination of local culture from the perspectives of film and television production and the cultural fusion between the two regions.

The “Experience Ningbo” exhibition, through the promotion of local cuisine and scenic beauty alongside displays of urban cultural and creative products, allowed audiences to experience Ningbo through both sight and taste. Many visitors expressed their desire to visit Ningbo in person.

This event created a “visible, tangible and portable” record of the city’s culture, further deepening cultural exchanges between Ningbo and Hong Kong. Moving forward, the film exhibition will tour more overseas cities, using the medium of film to promote Ningbo to the world.

Hashtag: #2026NingboImageOverseasExhibition

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/2026-ningbo-image-overseas-exhibition-concludes-successfully-in-hong-kong-china/

Posted on

Boao: Where the World Meets | Qionghai: Where Free Trade Thrives

Source: Media Outreach

QIONGHAI, CHINA – Media OutReach Newswire – 26 March 2026 – From March 24-27, the ” Boao: Where the World Meets, Qionghai: Where Free Trade Thrives” City Exhibition was held at Boao’s Dongyu Island Cultural Park. This marks the first major city showcase since the launch of Hainan Free Trade Port’s island-wide special customs operations—providing a panoramic window into Qionghai’s role as a core functional zone of the free trade port. Woven with the theme of global connection and open development, the exhibition turns policies and culture into immersive, sensory experiences through innovative technology and design.

The opening hall’s “Digital Twin Experience Pod” offers a glimpse into daily life in tomorrow’s Qionghai—all through the use of an identity card. The interactive “Cycle Through Qionghai” installation takes guests on a dynamic ride along the Wanquan River, through historic Nanyang hometowns—settlements built by overseas Chinese returning from Southeast Asia, and into Qionghai’s stunning coastal and mountain scenery.

A key highlight is the frontier technology from the Boao Lecheng International Medical Tourism Pilot Zone. Breakthrough innovations—including the world’s first automatic exophthalmometer, a non-invasive glucose monitor, a facial recognition system for genetic screening, and the Ruiwatch wearable—made their collective public debut, showcasing how “global medical innovations meet their first patients in China.”

As China’s only Medical Tourism Special Zone, Qionghai is not just a hub of medical “tech marvels”—it is a natural wellness destination. It brings together world-class medical devices, privileged treatment policies, and international health management systems, making “access to global cutting-edge healthcare” an everyday reality. From Lecheng’s precision medicine to seaside healing, from Traditional Chinese Medicine wellness to sports recovery, Qionghai is building an integrated ecosystem of medical care, wellness, tourism, and living.

With the Free Trade Port now in full operation, this coastal city invites health seekers worldwide to begin a journey of total renewal—where advanced medicine meets natural vitality, right here in Qionghai.

Hashtag: #CultureandTourismofGuizhouProvince #Qionghai

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/boao-where-the-world-meets-qionghai-where-free-trade-thrives/

Posted on

Wellcome and COFCO Hong Kong Announce Strategic Partnership Target First-Year Sales to Exceed HK$100 Million

Source: Media Outreach

HONG KONG SAR – Media OutReach Newswire – 26 March 2026 – Wellcome and COFCO Corporation Limited (“COFCO”) held a strategic cooperation agreement signing ceremony, announcing the establishment of a long-term partnership. The collaboration will strengthen cooperation across the supply of quality food products, brand and marketing initiatives, supply chain operations and elevating the overall customer consumption experience.

Curtis Liu, Chief Executive Officer, Food at DFI Retail Group (back row, fifth from left) and Mr. Lijun Qing, Vice President at COFCO Corporation Limited (back row, third from right) attended the signing ceremony with their teams to announce the strategic partnership

COFCO is an international agribusiness with a fully integrated food supply chain, underpinned by strong upstream sourcing capabilities and extensive supply chain management expertise. Wellcome is Hong Kong’s leading supermarket chain with the city’s largest store network. By leveraging their complementary strengths, the partnership aims to further enhance the supply of quality food products and offer customers a wider selection of fresh, great‑value choices.

Looking ahead, the two parties will focus on collaboration across four key areas:

  • First, strengthening the direct supply of quality products, with a diverse range of premium food products under COFCO prioritised for listing across Wellcome’s sales channels. This will expand offerings in key categories such as rice, flour, edible oils, dairy products, meat, alcoholic beverages, tea and beverages.
  • Second, enhancing supply chain efficiency by leveraging Wellcome’s local delivery and store network to accelerate the flow of fresh and fast‑moving consumer goods.
  • Third, driving joint brand and marketing initiatives, including new product launches, festive promotions and campaigns promoting healthy eating.
  • Fourth, strengthening food quality and safety management by strictly adhering to food safety standards and enhancing product traceability mechanisms, jointly safeguarding customers’ food safety.

At present, the key areas of cooperation include Mengniu dairy products, Fortune edible oil, Meilin canned food, and Joycome meat. In 2026, sales of COFCO’s products at Wellcome are expected to exceed HK$100 million. COFCO will prioritise supplying Wellcome with a broader range of quality products, while Wellcome will leverage its extensive local retail network to support COFCO with a stable and scalable sales channel in Hong Kong.

Through this partnership, both parties aim to provide customers with greater peace of mind and a wider range of quality food products, responding to Hong Kong families’ growing demand for better living. The first phase of the partnership’s promotional rollout features Joycome chilled pork, delivered fresh daily and offered at a long‑term promotional price of HK$28. Available from today at all Wellcome stores, the product is sourced directly from its origin, enabling Wellcome to offer customers produce of the highest quality.

Curtis Liu, Chief Executive Officer, Food, at DFI Retail Group, said: “This partnership between Wellcome and COFCO brings together the complementary strengths of both parties — COFCO’s robust food supply chain and Wellcome’s strong online and offline retail network. By combining these capabilities, we can further strengthen the stable supply of quality food products and offer customers a broader range of fresh products at great value.”

COFCO (Hong Kong) Limited’s spokesperson said: “The establishment of this long‑term strategic partnership with Wellcome fully leverages COFCO’s strengths in food supply chain capabilities and product resources, together with Wellcome’s territory‑wide retail network, enabling a wider range of quality food products to be supplied to the Hong Kong market more efficiently. COFCO will continue to provide Wellcome with a diverse and high‑quality product offering, working together to meet local households’ needs for food quality and supply stability.”

http://www.wellcome.com.hk
https://www.linkedin.com/company/wellcome-hong-kong/
https://www.facebook.com/wellcome.supermarket
https://www.instagram.com/hkwellcome/

Hashtag: #WellcomeHK #COFCO

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/wellcome-and-cofco-hong-kong-announce-strategic-partnership-target-first-year-sales-to-exceed-hk100-million/

Posted on

InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit

Source: Media Outreach

BEIJING, CHINA – EQS Newswire – 26 March 2025 – InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the annual results for 2025 as of December 13, 2025.

2025 marked InnoCare’s 10th anniversary and a milestone year of transformative growth and strategic execution. The Company achieved its first full year profitability, secured two new drug application (NDA) approvals, enhanced market penetration of its core products, accelerated globalization, and made breakthroughs across multiple pipelines. With numerous “China First” achievements, InnoCare continues to accelerate its 2.0 development strategy, demonstrating its strong ability to translate scientific innovations into sustainable long-term growth.

Financial Highlights

  • Revenue grew 135.3% year-on-year to RMB 2,375 million[1] in 2025, mainly driven by robust commercial growth and two strategic business development (BD) deals.
  • Profit reached RMB 644 million, achieving profitability for the first time, mainly due to significant commercialization growth and global out-licensing deals.
  • Gross Profit Margin increased by 5.7 percentage points to 92%.
  • Research and Development Investment increased by 16.9% to RMB 952 million in 2025, reflecting advancements of multiple Phase III registrational trials, as well as increased investments in new technology platforms such as ADCs and molecular glue.
  • Cash and Related Accounts Balance[2] stood at approximately RMB 7.8 billion as of December 31, 2025 and achieved positive operating cash flow for the first time. This strong cash position provides InnoCare with the flexibility to expedite global clinical development of key assets and invest in new technology platforms.

Accelerating Globalization with Transformative Deals

In 2025, InnoCare accelerated the implementation of its globalization strategy, unlocking global value of its core pipeline with two out-licensing deals, further enhancing the Company’s global influence and financial performance, and marking a significant step forward in its global expansion.

On Oct. 8, InnoCare entered into a transformative licensing agreement with Zenas for its autoimmune disease pipeline, including orelabrutinib. The agreement includes up to US$100 million in upfront and near-term milestone payments, and up to 7,000,000 shares of Zenas common stock, with a total deal value exceeding US$ 2 billion, setting a new record for small molecule autoimmune out-licensing in China.

This strategic collaboration marks a significant milestone in InnoCare’s globalization journey and will leverage shared focus to accelerate the global Phase III clinical development of orelabrutinib for the treatment of primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS), maximizing its clinical and commercial value worldwide, and advance a novel oral IL-17 AA/AF inhibitor and a brain-penetrant oral TYK2 inhibitor into clinical trials.

In addition, InnoCare entered into a licensing agreement with Prolium to further its global presence in 2025. In March 2026, Prolium announced first dosing of healthy volunteers in an ongoing single ascending dose study of ICP-B02 (PRO-203) and expects to initiate a multinational Phase I/II study of ICP-B02 in systemic sclerosis (SSc) in the second quarter of 2026, with additional studies in B-cell-driven autoimmune disease expected to follow.

Dr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, “Building on an inspiring decade of solid growth, we have continuously enhanced our fully integrated platform ranging from original innovation, clinical development, commercialization, manufacturing, to business development, achieving our strategic goal of break-even ahead of schedule, marking a significant milestone in our development history. As we enter our 2.0 phase of rapid development, we are focused on key strategic priorities, including securing approvals for five to six innovative drugs, advancing three to four products globally, and progressing five to ten differentiated molecules into clinical trials. We will further accelerate globalization, significantly increase revenue, and deliver more high-quality innovative therapies to benefit patients worldwide. “

Building A Leading Franchise in Hemato-Oncology

In 2025, InnoCare made significant progress toward building a leading hemato-oncology franchise, driven by advances in commercial execution, late-stage clinical development, and global expansion.

InnoCare continued to strengthen its commercial portfolio with orelabrutinib approved for first line chronic lymphocytic leukemia/small lymphocytic lymphoma (1L CLL/SLL) and successfully included in the updated National Reimbursement Drug List (NRDL), while tafasitamab became the first CD19 antibody approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) in China. As a result, drug sales increased by 43.4% to RMB 1,442 million in 2025.

Mesutoclax (ICP-248), the first BCL2 inhibitor granted Breakthrough Therapy Designation in China, continues to advance across multiple indications, including CLL/SLL, mantle cell lymphoma (MCL), acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS), with clinical trials ongoing in China and globally. Together, these three assets form the core of InnoCare’s hemato-oncology strategy, supporting near-term revenue growth with a pipeline of differentiated, late-stage therapies.

Orelabrutinib

Orelabrutinib serves as a backbone therapy in InnoCare’s extensive hemato-oncology pipeline. Its newly approved 1L CLL/SLL indication has been included in the NRDL and is recommended as a Class I treatment in the Chinese Society of Clinical Oncology (CSCO) Diagnosis and Treatment Guidelines for Malignant Lymphoma. With all four approved indications now covered under the NRDL, orelabrutinib offers stable annual treatment costs, benefiting more lymphoma patients.

The commercial team further strengthened execution capabilities and sharpened strategic focus, delivering strong sales performance throughout 2025. Improved market penetration and operational discipline laid a solid foundation for sustained revenue growth and long-term commercial success.

Internationally, orelabrutinib continued to expand its regulatory footprint, with approval granted for relapsed or refractory marginal zone lymphoma (R/R MZL) in Singapore and NDA submission for R/R MCL successfully completed in Australia.

Tafasitamab

In May 2025, the tafasitamab regimen received NDA approval for adult patients with R/R DLBCL, representing the first CD19 antibody therapy approved in China for this indication and a key addition to InnoCare’s commercial portfolio.

Building on the initial commercial launch in September 2025, 2026 will mark the first full year of tafasitamab sales in China. Moreover, tafasitamab has been included as a Class II recommendation in the CSCO Guidelines, which will help address unmet clinical needs in this patient population and provide meaningful benefits.

Mesutoclax (ICP-248)

As the first BCL2 inhibitor granted BTD in China, mesutoclax has rapidly advanced across multiple registrational studies. The Phase III combination regimen with orelabrutinib for 1L CLL/SLL completed patient enrollment within 10 months, demonstrating strong clinical execution. This fixed-duration combination regimen has the potential to deliver deeper remissions, bringing hope for clinical cure and representing a promising treatment option.

A registrational trial in BTK inhibitor-treated MCL is progressing rapidly, and a Phase III randomized, double-blind, multicenter study of mesutoclax in combination with orelabrutinib versus pirtobrutinib (a reversible BTK inhibitor) in r/r MCL is expected to commence in 2026.

Global development of mesutoclax in AML and MDS is progressing across China, U.S., and Australia. The global AML and MDS markets are projected to reach US$8 billion[3] and US$11 billion[4] by 2034 respectively.

Mesutoclax, as a monotherapy or in combination with orelabrutinib, demonstrated a favorable safety profile for CLL/SLL across all dose levels tested. In the CLL/SLL patients receiving mesutoclax in combination with orelabrutinib, the overall response rate (ORR) was 100%, the complete response rate (CRR) was 57.1%, and the peripheral blood uMRD rate at 36-week was 65%. The clinical data from mesutoclax monotherapy demonstrated potential best in class efficacy in MCL patients, particularly in heavily treated patients with BTK inhibitor refractory. Among MCL patients who were BTK inhibitor-refractory, the ORR was 84.0% and the CRR was 36.0%. Mesutoclax in combination with orelabrutinib demonstrated a consistently favorable safety profile across B-cell malignancies (MCL, MZL, CLL/SLL). This oral, chemo-free regimen has the potential to establish a novel therapeutic option for B-NHLs. Updated data will be presented at 2026 American Society of Clinical Oncology (ASCO) annual meeting.

The combination of mesutoclax and azacitidine demonstrated a favorable safety profile and encouraging anti-tumor activity not only in AML but also in MDS patients. Among 35 evaluable treatment-naive AML patients, the regimen achieved an 85.7% composite CR rate and an 86.7% uMRD rate, with no mortality observed with 90 days. Preliminary data among MDS patients is also promising. There were no dose-limiting toxicities (DLT) or tumor lysis syndrome (TLS) events. Detailed data to be presented at 2026 ASCO annual meeting.

Developing B-cell and T-cell Pathways in Autoimmune Diseases

Autoimmune diseases can affect almost every organ in the body and may arise at any stage of life. The global market for autoimmune disease therapeutics is anticipated to reach $185 billion by 2029[5]. The Company has fortified its powerful discovery engine on cutting-edge global targets for the development of autoimmune therapeutics through B-cell and T-cell pathways, with the aim of delivering first-in-class and/or best-in-class treatments to address the massive unmet clinical needs and strong market potential in China and globally.

Orelabrutinib

Immune Thrombocytopenia (ITP): With over 200,000 new cases globally each year, including 60,000 in China, ITP represents a significant unmet medical need. The pivotal Phase III study has been completed, and the Company expects to submit the NDA application in the first half of 2026. ITP represents an important expansion of orelabrutinib from hematologic malignancies into autoimmune hematologic diseases, unlocking its enormous commercial potential. By leveraging the BTK inhibitor’s advantage in ITP, such as decreased macrophage-mediate platelet destruction and reduced production of pathogenic autoantibodies, orelabrutinib is well positioned to become a preferred BTK inhibitor in the field of ITP.

Systemic lupus erythematosus (SLE): There are about 8 million SLE patients worldwide. Orelabrutinib is the first BTK inhibitor to demonstrate significant efficacy in a Phase II clinical trial for SLE. The Phase IIb study met its primary endpoint, and a Phase III registrational study was initiated in the first quarter of 2026. Under stringent steroid-tapering requirements, orelabrutinib 75 mg once daily (QD) achieved a statistically significant improvement in SLE Response Index-4 (SRI-4) rate compared with placebo at Week 48 (57.1% vs. 34.4%, p

Multiple Sclerosis (MS): The US SPMS and PPMS market exceeds US$12 billion[6], representing a significant commercial opportunity. Based on the deal, InnoCare has been cooperating with Zenas to accelerate two global Phase III clinical trials of orelabrutinib for the treatment of PPMS and SPMS, further unleashing its global value in autoimmune diseases.

  • Initiated Orelabrutinib PriMroSe PPMS trial, a Phase III, global registration-directed, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of orelabrutinib in patients with PPMS in the third quarter of 2025. More information on the Phase III PriMroSe trial (NCT07067463) is available at clinicaltrials.gov.
  • Orelabrutinib Monarch trial for non-active SPMS (naSPMS) is planned, a Phase III, global registration-directed, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of orelabrutinib in patients with naSPMS is expected to initiate in the first quarter of 2026. More information on the Phase III Monarch trial (NCT07299019) is available at clinicaltrials.gov.

Two TYK2 Inhibitors

The global dermatology drug market has enormous potential, with over 500 million patients suffering from dermatological diseases worldwide. By 2035, the global dermatology market size is projected to reach nearly US$100 billion. InnoCare is well positioned to capture this opportunity with two TYK2 inhibitors targeting multiple high-value indications, including atopic dermatitis (AD), psoriasis, vitiligo, nodular prurigo (PN), urticaria (CSU), cutaneous lupus erythematosus (CLE), and other dermatological diseases. The global AD market is projected to reach $30 billion[7] by 2030, the vitiligo market $3 billion[8] by 2032, the CSU market $3 billion[9] by 2029, the psoriasis market $58 billion[10] by 2032, the PN market $3 billion[11] by 2034, and CLE market US$ 7.9 billion[12] by 2032.

Soficitinib (ICP-332)

The Phase III clinical study of soficitinib in patients with moderate to severe atopic dermatitis (AD) completed patient enrollment, with data readout expected in mid-2026. The Phase II clinical study of soficitinib in patients with vitiligo has also completed patient enrollment. Additional studies in prurigo nodular, urticaria, and psoriasis are progressing rapidly. As a result, soficitinib is expected to deliver a series of clinically meaningful data catalysts in 2026.

Data from the Phase II clinical trial of soficitinib in patients with moderate-to-severe AD were published in JAMA Dermatology in January 2026. The journal concluded that soficitinib demonstrated a favorable safety profile and encouraging efficacy in patients with AD.

Soficitinib achieved multiple efficacy endpoints in the study. The percentage improvement from baseline in EASI at Week 4 were 78.2% in the soficitinib 80 mg group, 72.5% in the soficitinib 120 mg group, and 16.7% for those receiving placebo. There was a statistically significant higher EASI-75 response rate with both soficitinib doses (64.0% for each; difference vs placebo, 56.0%) than with placebo and a greater percentage of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA) score of 0 or 1 and improvement of 2 or more points at Week 4 in the soficitinib 80 mg group vs placebo (36.0%; difference vs placebo, 32.0%, P=0.005). Meanwhile, soficitinib demonstrated rapid relief of pruritus and significant improvement in quality of life. Substantial reductions in Pruritus NRS severity and frequency scores were observed on Day 2 of treatment compared to placebo, with continued improvement over time, peaking at Week 4 for both severity and frequency (all P

ICP-488

The Phase III clinical study in psoriasis has completed patient enrollment, and the Phase II trial for CLE is progressing rapidly. The IND for Sjögren’s syndrome has been submitted, and additional indications and combination strategies are under evaluation.

Data on ICP-488 for the treatment of patients with moderate-to-severe plaque psoriasis has been released at the 2025 AAD Annual Meeting as a late-breaking oral presentation. The study results demonstrated that ICP-488 is highly effective in treating psoriasis at both the 6 mg QD and 9 mg QD doses. Moreover, ICP-488 exhibited favorable safety and tolerability profiles, reinforcing its potential as a valuable treatment option for moderate-to-severe psoriasis patients.

At week 12, the percentage of patients achieving PASI 75 was significantly superior in the ICP-488 6 mg QD group (77.3%) and the 9 mg QD group (78.6%) than that of the placebo group (11.6%); the percentages of subjects achieving PASI 90 and sPGA of 0 (clear) or 1 (almost clear) were also significantly higher in the ICP-488 6 mg QD group (36.4%, 70.5%) and 9 mg QD group (50.0%, 71.4%) compared to the placebo group (0%, 9.3%).

ICP-538

The first healthy volunteer has been dosed in a clinical trial of ICP-538, a VAV1-directed molecular glue degrader (MGD), in China. This is the first VAV1 degrader approved to enter clinical trials in China. ICP-538 is a novel, potent, highly selective, orally administered molecular glue degrader targeting VAV1, a key protein downstream of T-cell and B-cell receptors. ICP-538 induces rapid and efficient degradation of the VAV1 protein in a dose-dependent manner by selectively mediating the formation of a ternary complex between the CRBN E3 ubiquitin ligase and the VAV1 protein. ICP-538 will be developed for the treatment of autoimmune diseases, such as inflammatory bowel disease, systemic lupus erythematosus, and multiple sclerosis. Currently, there are no approved VAV1-targeted therapies globally.

ICP-054

The IND application of ICP-054 (ZB021), a novel oral IL-17AA/AF inhibitor, was submitted. ICP-054 is a novel, oral, highly potent and selective IL-17AA/AF inhibitor with significant therapeutic potential in autoimmune and inflammatory diseases. ICP-054 can effectively block the signal transduction pathways of IL-17AA homodimer and IL-17AF heterodimer, thereby inhibiting the release of pro-inflammatory cytokines and chemokines, exerting an anti-inflammatory effect. Simultaneously, it reduces excessive proliferation of keratinocytes and inflammatory cell infiltration, improving skin lesions and thus suppressing the occurrence of autoimmune and inflammatory diseases.

Under the BD agreement, Zenas holds exclusive rights to develop, manufacture and commercialize the oral, IL-17AA/AF inhibitor in all territories outside Greater China and Southeast Asia.

Building Innovative Solid Tumor Assets

InnoCare has been building a robust and diversified portfolio to address significant unmet medical needs across multiple tumor types. The Company is committed to combining targeted small molecules with next-generation antibody-drug conjugates (ADCs) to maximize clinical benefit while minimizing systemic toxicity. The R&D team aims to focus on tumor types with high unmet needs, and to develop therapies that are differentiated in mechanism of action, potency, and safety profile. InnoCare’s proprietary ADC technology platform, alongside promising precision medicine candidates like zurletrectinib, positions the Company to establish a strong presence in the field of solid tumor treatment.

Zurletrectinib (ICP-723)

Zurletrectinib, a next generation TRK inhibitor, represents InnoCare’s first approved therapy in solid tumors and its third innovative product approved for marketing. Zurletrectinib is indicated for adult and adolescent patients (12–18 years) with NTRK gene fusion-positive tumors.

In the registrational clinical trial for patients with NTRK fusion-positive solid tumors, zurletrectinib demonstrated outstanding efficacy and a favorable safety profile. The study results showed an ORR of 89.1%, a disease control rate (DCR) of 96.4%, and 24-month progression-free survival (PFS) and overall survival (OS) rates of 77.4% and 90.8% respectively.

InnoCare expects to submit NDA for pediatric patients (2 years

In-House Developed Antibody-Drug Conjugate (ADC) Platform

The Company has developed a cutting-edge ADC platform with proprietary linker-payload (LP) technologies, aimed at the delivery of potent and targeted therapies for cancer treatment. This platform allows for the creation of highly differentiated ADCs with improved efficacy and safety profiles. Key features of the platform include:

  • Irreversible bioconjugation: ensuring stable antibody-linker bioconjugation for improved stability.
  • Hydrophilic linker: enhancing ADC stability and achieving a high drug-to-antibody ratio (DAR) of 8.
  • Novel payload: incorporating highly potent cytotoxic payloads with a strong bystander killing effect.

The platform is expected to deliver ADCs with strong tumor-killing efficacy and an adequate therapeutic window, thereby broadening treatment options for cancer patients and improving their clinical outcomes. As the platform continues to evolve, the Company is poised to expand its portfolio with multiple differentiated ADC candidates, further advancing precision medicine in oncology.

ICP-B794: A Novel B7-H3 Targeted ADC for Solid Tumors

InnoCare is advancing the Phase I dose escalation trial of novel B7-H3 targeted ADC, ICP-B794. ICP-B794 is a novel ADC comprising a humanized anti-B7-H3 monoclonal antibody conjugated to a potent in-house developed payload via a protease-cleavable linker. This combination ensures precise targeting of tumor cells while minimizing off-target effects, offering a promising treatment for solid tumors such as lung cancer, esophageal cancer, nasopharyngeal cancer, head and neck squamous cell carcinomas, prostate cancer, and others. ICP-B794 has demonstrated superior anti-tumor activity in animal models compared with other ADCs, and exhibited significant tumor-killing effects even in large tumors.

Early clinical observations indicate favorable pharmacokinetics and tolerability, with preliminary signs of antitumor activity, which validate the Company’s proprietary ADC platform for solid tumor development.

ICP-B208: A Novel CDH17 Targeted ADC for Solid Tumors

Building on the encouraging efficacy and safety of ICP-B794, the second ADC candidate, ICP-B208, is designed to target CDH17, a calcium-dependent cell adhesion protein that plays a key role in tumor cell proliferation, migration, and metastasis. Its tumor-restricted expression and functional role in cancer biology make CDH17 an attractive and differentiated target for ADC therapy, enabling the delivery of potent cytotoxic payloads specifically to tumor cells while minimizing systemic toxicity, which can be developed for the treatment of gastrointestinal cancers, including gastric, colorectal, pancreatic ductal adenocarcinoma, and cholangiocarcinoma. Preclinical studies show that ICP-B208 demonstrates good anti-tumor activity even in CDH17-low tumors. The IND application has been submitted in March 2026.

InnoCare plans to submit at least two more ADC INDs within 2026, further expanding its differentiated solid tumor pipeline.

To know more about the detailed financial data and business updates of InnoCare 2025 annual results, please log in to https://www.innocarepharma.com/en/investor/home .

Conference Call Information

InnoCare will host a conference call at 8:30 p.m. Beijing time on March 25 in English and at 9:00 a.m. Beijing time in Chinese on March 26, 2025. Participants must register in advance of the conference call. Details are as follows:

For English conference call, please register through the below link:
https://goldmansachs.zoom.us/webinar/register/WN_rVCbaOqMSM-QJQlfzlTEvw

For Chinese conference call, please register through the below link:
https://s.comein.cn/qz7duugd

Forward-looking Statement

This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management’s intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.

[1] The financial figures in this article are based on Hong Kong Financial Reporting Standards

[2] Include cash and bank balances, other current assets, financial assets among other non-current assets, and interest receivable

[3] Global Growth Insights

[4] Nova One Advisor, Insight Code: 8817

[5] iHealthcareAnalyst, Inc., Oct. 3, 2023

[6] Zenas estimate based on reported prevalence and current pricing of B cell therapies approved for MS

[7] Grand View Research

[8] Data Bridge Market Research

[9] The Business Research Company

[10] Fortune Business Insights

[11] Global Market Insights

[12] Data Bridge Market Research

Hashtag: #InnoCare

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/innocare-releases-2025-results-and-business-highlights-achieving-first-annual-profit/

Posted on

Zuellig Pharma Reinforces Commitment to Japan through Its New Misato Depot, Advancing Clinical Logistics and Sourcing Excellence

Source: Media Outreach

MISATO, JAPAN – Media OutReach Newswire – 26 March 2026 – Zuellig Pharma today announced the successful relocation of its new clinical depot to Misato, strengthening its ability to deliver global quality standards with local operational agility and further strengthening its clinical supply capability across Asia Pacific. Japan remains one of the region’s preferred locations for clinical research, underpinned by its strong focus on medical advancement, rigorous ethical standards and commitment to healthcare.

Medical innovation across the region continues to accelerate, with China, India, Australia, Japan, South Korea, Taiwan and Singapore emerging as key pillars of Asia Pacific’s clinical trial ecosystem over the past five years[1]. Against this backdrop, the move in Japan reinforces Zuellig Pharma’s commitment to supporting sponsors and clients with reliable, compliant and seamless access to Japan – advancing its broader mission to make healthcare more accessible.

The new depot will bring together Zuellig Pharma’s established knowledge assets, operational excellence, and clinical logistics and sourcing expertise. Backed by a highly experienced and expert-led local team, the depot delivers precision project management tailored to Japan’s intricate regulatory and logistical requirements, while enabling smoother coordination for multi-market studies as the clinical landscape continues to evolve.

“As sponsors and clients increasingly run multi-market studies, they need clinical supply partners that can deliver consistency across borders while navigating local complexity,” said John Graham, Chief Executive Officer, Zuellig Pharma. “This relocated depot will strengthen access to Japan within our regional network, helping us execute with greater reliability, compliance, and speed across the region.”

The Misato clinical depot will also provide a streamlined, turnkey solution for global sponsors seeking rapid and compliant market entry into Japan. Sponsors will benefit from the same rigorous operational excellence, regulatory adherence, and service consistency delivered by Zuellig Pharma’s strategic network of clinical depots, without the overhead of building or managing costly standalone facilities. This milestone supports Zuellig Pharma’s ongoing efforts to accelerate clinical development and improve patient access to innovative therapies across Asia Pacific.

With this strategic move, Zuellig Pharma further strengthens its position as a trusted partner for global clinical development, combining scale, expertise, and agility whilst delivering high-quality, compliant clinical logistics and sourcing solutions across Asia Pacific.

[1] https://www.clinicaltrialsarena.com/features/apac-clinical-trials-beyond-china

https://www.zuelligpharma.com/
https://www.linkedin.com/company/zuellig-pharma

Hashtag: #ZuelligPharma #ClinicalTrials #ClinicalResearch #Healthcare #Pharmaceuticals #ColdChain #Logistics

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/zuellig-pharma-reinforces-commitment-to-japan-through-its-new-misato-depot-advancing-clinical-logistics-and-sourcing-excellence/

Posted on

Contractor Confidence Rises Amid Strengthening Office Demand Across Asia Pacific

Source: Media Outreach

  • Contractor Sentiment Survey shows 70% of respondents expect improved market conditions in 2026
  • Office fit out costs diverge across the region with Japan and Taipei posting largest year-on-year increases while costs in Hong Kong held steady

HONG KONG SAR – Media OutReach Newswire – 26 March 2026 – Cushman & Wakefield’s Asia Pacific Office Fit Out Cost Guide 2026 highlights a clear shift in regional market dynamics, with sentiment strengthening and activity levels improving across several key markets. Contractor confidence has risen year-on-year, with 70% of the respondents to the firm’s annual Contractor Sentiment Survey anticipating improved conditions in 2026. This positive sentiment is further supported by the stronger‑than‑expected 92 million square feet of office absorption in 2025 and a tightening construction pipeline outside India.

Of the 180 survey respondents, nearly two thirds reported project backlogs of around six months, reflecting improving project delivery conditions across the region. While Japan and Indonesia remain outliers with longer backlogs, most markets expect stabilisation or slight improvement in delivery timelines in 2026. This alignment between contractor sentiment and strengthening occupier demand points to a more balanced and active project environment emerging across Asia Pacific.

Ranee Ng, Executive Director, Head of Project & Development Services, Hong Kong said: “As Hong Kong’s property market evolves, occupiers are seeking practical, scalable fit out strategies that deliver efficiency in high density environments. There is a clear shift toward flexible designs that can rapidly adapt to changing workforce behaviours and policy updates, while demand for sustainable materials, energy efficient construction and smart building technologies is accelerating innovation. These trends are creating a more resilient fit out ecosystem where disciplined cost management and value driven delivery allow clients to achieve compelling performance outcomes without sacrificing quality.”

Fit Out Cost Movements (YoY, 2025 → 2026)

The 2026 Guide reported a divergence in city level fit out costs (measured in USD per sq ft) across the region:

  • Costs rising: Japan and Taipei posted the largest year-on-year increases
    (Tokyo: USD 215 vs USD 195; Taipei: USD 145 vs USD 110)
  • Costs easing: Mainland China and South Korea saw declines
    (Shenzhen: USD 87 vs USD 94; Seoul: USD 130 vs USD 156)
  • Costs steady: Singapore (USD 140) and Hong Kong (USD 160) remained largely unchanged
  • Best value: India remains the region’s most cost competitive market, with most major cities ranging USD 65–73 per sq ft

These cost movements reflect evolving local construction dynamics and broader economic adjustments influencing material, labour and delivery markets across Asia Pacific.

APAC Office Market Dynamics

Even as office demand across APAC surged in 2025, Cushman & Wakefield also noted a substantial contraction in new office supply outside India. Development pipelines have moderated sharply due to rising construction costs and reduced project feasibility, intensifying competition for prime space. As supply tightens, vacancy rates in high quality buildings – particularly in core CBD locations – are expected to trend lower, reinforcing the ongoing flight to quality amongst occupiers.

Report author and Head of International Research, APAC & EMEA, Dr. Dominic Brown said: “After a resilient 2025, the Asia Pacific office market is now transitioning into a more stable phase, supported by a gradual return of business confidence. Coupled with the tightening supply pipeline outside India, which is reshaping the competitive landscape for high quality space, these collective shifts indicate a meaningful turning point for the region in 2026, with both occupiers and investors positioned for renewed momentum.”

Notes:

  1. Data and pricing benchmarks in the guide reflect market conditions as of December 2025. For insights on the Middle East conflict, please refer to Cushman & Wakefield’s Middle East Conflict: Implications for Energy, Inflation, and CRE.
  2. Cushman & Wakefield publishes Office Fit Out Cost Guides for APAC, EMEA and the Americas, which are all available [here].

Hashtag: #CushmanWakefield

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/contractor-confidence-rises-amid-strengthening-office-demand-across-asia-pacific/

Posted on

Felix Y. Manalo Foundation: How Education-Focused Humanitarian Programs Break Cycles Of Poverty

Source: Media Outreach

MANILA, PHILIPPINES – ACCESS Newswire – 25 March 2026 – Poverty is possibly the most significant limiting factor in terms of access to learning, healthcare, and economic mobility. In less-advantaged communities, education-centered humanitarian programs are necessary to address these constraints.

The Felix Y. Manalo Foundation operates at the forefront of these initiatives by building practical skills, supporting youth development, and strengthening community capacity. In its role as a catalyst for long range social progress, it incorporates academic support, volunteer service, and community outreach within its broader humanitarian mission.

Expanding Access to Learning Resources

For many low-income households, limited access to books, digital tools, and structured learning environments remains a major hindrance to growth and development. Through its educational outreach programs, organizations such as the Felix Y. Manalo Foundation provide learning materials, organize community-based activities, and support youth engagement initiatives that reinforce academic participation.

These efforts can greatly reduce disparities that commonly exist between urban and underserved communities. By providing students with consistent access to educational resources, the foundation helps improve attendance, increase confidence, and pave the way for long-term career paths.

Integrating Skills Development With Community Service

The Felix Y. Manalo Foundation’s approach to education extends beyond classroom instruction, delving into practical experience that encourages problem-solving and teamwork. Program participants have the opportunity to join service projects that introduce responsibility, planning, and communication.

The foundation also implements environmental programs, food distribution activities, and local outreach events, all of which provide structured opportunities for applied learning. By integrating mentorship with volunteer guidance, the organization teaches participants valuable, transferable skills. Consequently, the programs foster workforce readiness while strengthening civic awareness and social responsibility.

Stabilizing Families Through Supportive Outreach

Organizations such as the NIH attest to the beneficial impact of household stability on student performance and long-term educational attainment. Food assistance initiatives, health awareness programs, and community support events can all reduce financial strain and promote well-being among disadvantaged families.

The Felix Y. Manalo Foundation’s coordinated food donation programs and volunteer engagement activities in Canada demonstrate how relief efforts enhance household resilience. By addressing basic needs alongside educational outreach, the organization helps develop environments where children can focus on learning rather than worry about their immediate survival.

Operational Discipline and Program Sustainability

The Felix Y. Manalo Foundation’s community service amply demonstrates the value of structured planning, transparent governance, and reliable volunteer coordination. To ensure sustainable impact, accountability has always been core to the organization’s project management, financial stewardship, and compliance practices.

The foundation’s training frameworks are designed to ensure consistent service quality and reinforce ethical standards. Through its organizational oversight, the organization fosters donor confidence and maintains continuous improvement in its education-focused programs.

Through its various education-centred humanitarian programs, the Felix Y. Manalo Foundation directly contributes to economic mobility by improving home stability, increasing community participation, and strengthening individual capability. By integrating learning access with service engagement and operational accountability, the organization ensures the community’s long-term development is measurable and scalable.

Structured educational outreach, volunteer leadership development, and responsible governance are among the practical measures implemented by the Felix Y. Manalo Foundation. Each is one of many ways the organization aims to break cycles of intergenerational poverty while supporting inclusive community growth.

Hashtag: #FelixY.ManaloFoundation

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/felix-y-manalo-foundation-how-education-focused-humanitarian-programs-break-cycles-of-poverty/

Posted on

ASMALLWORLD Introduces New Marriott Bonvoy® Benefit for Members

Source: Media Outreach

ZURICH, SWITZERLAND – EQS Newswire – 25 March 2026 – ASMALLWORLD expands its offering with a new Marriott Bonvoy reward expanding its curated portfolio of premium travel benefits and loyalty rewards available across the ASMALLWORLD travel ecosystem.

ASMALLWORLD members can now enjoy access to Marriott Bonvoy points as part of their membership benefits — 35,000 points (Advantage), 250,000 points (Prestige) and 500,000 points (Signature) — bringing added flexibility and value for members who want to elevate their hotel stays worldwide.

“This new benefit marks another important step in strengthening our global travel benefits portfolio and giving members more meaningful ways to unlock exceptional experiences,” said Zain Richardson, CEO of ASMALLWORLD. “By integrating Marriott Bonvoy points into our product offering, we are increasing choice and helping our members turn travel inspiration into memorable stays — whether for a long weekend or a once-in-a-lifetime journey.”

NEW MARRIOTT BONVOY BENEFIT FOR ASMALLWORLD MEMBERS

Marriott Bonvoy is Marriott International’s award-winning travel programme, spanning a global collection of hotel brands and destinations.

Through this partnership, ASMALLWORLD members can include Marriott Bonvoy points as part of their membership benefits, enabling them to use points toward stays that include the largest collection of luxury offerings, distinctive boutique properties, premium home rentals, and more. Members can also unlock once‑in‑a‑lifetime experiences through Marriott Bonvoy Moments , from exclusive Michelin‑starred culinary journeys to groundbreaking musical world tours. Expanded ways to redeem points range from Shop with Points to curated Tours & Activities, adding another layer of memorable experiences to the ASMALLWORLD membership proposition.

MARRIOTT BONVOY POINTS PACKAGES AVAILABLE TO MEMBERS

ASMALLWORLD members can access the following Marriott Bonvoy points packages as part of their membership selection:

To celebrate the launch of this new benefit, ASMALLWORLD members purchasing Advantage or Prestige memberships will receive a limited time award of 30% bonus points.

EXPANDING PREMIUM TRAVEL BENEFITS

This new benefit reinforces ASMALLWORLD’s commitment to offering members a curated suite of travel privileges across flights, hotels, experiences and lifestyle.

In addition to loyalty rewards, ASMALLWORLD members enjoy a range of premium benefits across the ASMALLWORLD ecosystem, including VIP hotel benefits, elite statuses, airport lounge access options and invitations to exclusive global events.

THE ASMALLWORLD GROUP

Centred around the ASMALLWORLD social network, the company operates a luxury travel ecosystem that serves discerning travellers and industry partners.

At its core, the ASMALLWORLD social network is the trusted community for modern luxury travellers, offering a platform to connect, share experiences and enjoy a wealth of travel privileges.

ASMALLWORLD members can engage through its app and website, receive travel inspiration, and meet in person at over 950 global ASMALLWORLD events every year, ranging from casual get-togethers, access to exclusive launches, galas, major global sporting events, and larger flagship weekend experiences hosted in iconic destinations such as Saint-Tropez and St. Moritz.

Beyond the social network, the ASMALLWORLD Group extends into bespoke travel planning, luxury hospitality, and strategic B2B collaborations. Through its diverse portfolio, the Group fosters a like-minded global community, curated opportunities, and tailored solutions, shaping the evolution of luxury travel.

Other businesses in the ASMALLWORLD travel ecosystem include:
ASMALLWORLD Collection, a high-end online hotel booking engine focused on the world’s most admired hotels, offering the unique “ASMALLWORLD VIP Rate,” which combines preferred rates with exclusive travel benefits and privileges.

ASMALLWORLD Bespoke Travel, a high-end travel agency offering personalised travel curation services.

ASMALLWORLD DISCOVERY, part of Global Hotel Alliance alongside 50 leading hotel brands, services independent hotels in providing access to the GHA DISCOVERY loyalty network

ASMALLWORLD Hospitality, a hospitality and management consultancy that supports owners and developers of hospitality assets throughout the different lifecycle stages of their assets, including acquisition, development, operations and exit.

First Class & More, a subscription-based smart luxury travel service that allows members to enjoy luxury travel at insider prices.

The World’s Finest Clubs, the world’s leading nightlife concierge offers its members VIP access to the most exclusive nightlife venues around the world.

Jetbeds, a premier booking platform specialising in affordable Business and First-Class flights, offering exclusive deals, expert advice and personalised service.

For more information, please visit:www.asmallworldag.com / www.asmallworld.com

CONTACTS
ASMALLWORLD AG
Seidengasse 20
8001 Zurich
Switzerland
info@asmallworldag.com

Pippa O’Keefe
Head of PR
+44 7990 824 249
pippa@asw.com

DISCLAIMER
The statements contained in this press release may constitute “forward-looking statements”. Such can be identified, for example, by the use of the words “may,” “will,” “should,” “plan,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “project,” “target,” “seek,” or “aim,” or the negative of these words or comparable expressions.

Forward-looking statements involve a number of known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Issuer or its industry to be materially different from any future results, level of activity, performance or achievements expressed or implied by such forward-looking statements.

The issuer undertakes no obligation to publicly update or revise any forward-looking statements contained herein, whether as a result of new information, future events or otherwise.

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/asmallworld-introduces-new-marriott-bonvoy-benefit-for-members/

Posted on

Tintri and Integration Plumbers Announce Groundbreaking Open-Source Integration to Unify Storage and IT Observability

Source: Media Outreach

Delivering unprecedented full-stack visibility, the new OpenTelemetry-based solution eliminates storage silos, accelerates troubleshooting, and empowers IT teams with a seamless, vendor-agnostic monitoring pipeline.

AMSTERDAM, NETHERLANDS – Media OutReach Newswire – 25 March 2026 – Tintri, innovator of the industry’s only workload-aware, AI-powered data management platform for virtualized and containerized workloads, today announced a strategic partnership with Integration Plumbers, observability integration specialists. Together, the companies have launched a highly anticipated, no-cost, and open-source integration designed to seamlessly connect Tintri’s intelligent VMstore platform to the modern monitoring ecosystems that enterprise IT teams rely on daily.

This collaboration marks a significant milestone in enterprise infrastructure management, bridging the historical gap between storage arrays and application-level observability. By leveraging open standards, Tintri and Integration Plumbers are delivering maximum visibility without the burden of proprietary dependencies.

The Problem: Too Many Dashboards, Not Enough Answers

In today’s hyper-complex, cloud-native IT environments, every minute of downtime or performance degradation translates directly to lost revenue and diminished user experience. When an incident occurs, rapid root-cause analysis is critical. However, for many organizations, determining whether a performance bottleneck originates in the application code, the network layer, or the underlying storage system is a convoluted, manual process.

Historically, storage monitoring has existed in a vacuum. Storage administrators utilize specialized, vendor-specific dashboards, while DevOps and Site Reliability Engineering (SRE) teams rely on entirely different platforms for application and infrastructure monitoring. This fragmentation forces teams to log into multiple disconnected tools, manually correlate timestamps, and engage in time-consuming cross-departmental coordination. The result is a bloated Mean Time To Resolution (MTTR), increased operational costs, and unnecessary architectural complexity. IT teams are burdened with managing disparate monitoring systems, redundant alerts, and separate credentials just to piece together a holistic view of their infrastructure.

The Solution: One Pipeline for Everything

The newly announced integration fundamentally transforms this paradigm by establishing a single, unified pipeline for all telemetry data. Built natively on OpenTelemetry, the rapidly adopted open industry standard for collecting, processing, and routing monitoring data; this solution ingests Tintri’s granular storage metrics directly into the existing observability pipelines that IT teams already use.

Rather than forcing engineers to consult a separate “storage only” application, this integration acts as a seamless data feed into a centralized command center. Tintri’s VMstore is architected to track performance at the level of individual virtual machines and containerized applications, eschewing the traditional, opaque LUN or volume-level metrics. The data it generates is uniquely detailed, context-rich, and immediately actionable.

This integration effortlessly surfaces VMstore’s rich telemetry in whatever monitoring platform an enterprise has already standardized on, such as Grafana, Datadog, Dynatrace, Prometheus, and any other OpenTelemetry-compatible tool.

Phil Trickovic, Senior Vice President, Tintri stated: “Storage telemetry has historically been stuck in vendor-specific silos. This integration changes that, giving platform and operations teams a unified view of their entire stack, including storage, without adding new tools or new contracts.”

What This Means in Practice: Tangible Business Value

The Tintri and Integration Plumbers partnership delivers immediate, measurable benefits to enterprise IT operations:

  • Faster Troubleshooting and Reduced MTTR: When an incident occurs, IT teams can now visualize storage performance data side-by-side with application and infrastructure telemetry in a single, unified dashboard. This contextualized view drastically cuts the time required to identify and remediate root causes.
  • Zero Additional Licensing Costs: The integration is designed to work flawlessly with the monitoring platforms customers already have deployed. No need to procure, deploy, or train staff on a separate, standalone storage monitoring product.
  • Total Freedom and Flexibility: Because the solution is built entirely on the OpenTelemetry open standard, customers are protected from vendor lock-in. Should an organization decide to migrate to a different monitoring vendor in the future, the transition requires only a simple configuration update, not a complete architectural overhaul.
  • Built to Last and Evolve: By contributing this integration directly to the open-source OpenTelemetry community, Tintri and Integration Plumbers foresee the tool continuously evolving alongside broader industry standards, rather than being constrained by a single vendor’s proprietary roadmap.

Under the Hood: Built on OpenTelemetry Standards

For platform engineers and technical architects, the integration is engineered as a standard OpenTelemetry Collector component. It intelligently harvests metrics from both physical VMstore appliances and the Tintri Global Center management platform via robust REST APIs.

Crucially, these metrics are meticulously mapped to OpenTelemetry semantic conventions. This standardization enables out-of-the-box correlation with Kubernetes environments and application-level telemetry. Standard Collector exporters facilitate the seamless routing of this data to any OTLP-compatible backend including Prometheus, ClickHouse, Datadog, and Dynatrace; requiring absolutely no modifications to the Tintri integration itself.

Demonstrating a profound commitment to the open-source ethos, the project will be officially contributed to the OpenTelemetry ecosystem. It is architected from the ground up for long-term community maintainability and strict compliance with OTEL project standards.

Trickovic elaborated “By combining Tintri’s workload-aware storage metrics with the OpenTelemetry ecosystem, we’re giving customers the unified observability they’ve been asking for – storage shouldn’t be the blind spot in your monitoring stack.”

Tintri and Integration Plumbers will be hosting a 60-minute deep dive into OpenTelemetry-native storage observability, including a live technical demo on April 15, 2026 at 10:00 AM PT / 1:00 PM ET. https://tintri.com/experience/tintri-integration-plumbers-4-15-26/

Hashtag: #Tintri #IntegrationPlumbers

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/tintri-and-integration-plumbers-announce-groundbreaking-open-source-integration-to-unify-storage-and-it-observability/

Posted on

Tintri and Platform9 Announce Joint Solution for containerized and hypervisor-based workloads.

Source: Media Outreach

New all-in-one platform to help businesses develop and deploy at scale with maximum ROI

CHATSWORTH, US – Media OutReach Newswire – 25 March 2026 – Tintri, the innovator in workload-aware, AI-powered data management, and Platform9, the leader in simplifying enterprise private clouds, today announced a strategic partnership to deliver a bundled AI-ready infrastructure solution that streamlines deployment and reduces operational costs. The out-of-the-box offering makes it simple for enterprises to stand up and scale modern AI systems without the complexity of traditional stacks.

The Problem: AI Is Getting Expensive

Running AI to process and analyze data in real time, requires moving enormous amounts of data at extremely high speeds. Existing infrastructure wasn’t built to manage the sheer volume and velocity of data required for on-demand inferencing and ongoing model training, ultimately causing slowdowns and driving up operational costs. Tintri and Platform9 directly addresses these critical bottlenecks in the by cutting the cost per AI transaction, as low as possible.

What’s in the New Platform

The new offering has two main parts:

1. A powerful data center component built on standard server hardware that can run multiple types of virtual machines and containerized applications side-by-side, without resource impacts. Tintri’s patented technology monitors each application individually, making sure the most critical ones always get the resources they need.

2. An edge AI component designed for capturing real-time data to continuously learn and update inference models.

A core component of the platform is Tintri VMstore, which uniquely runs multiple virtualization platforms and Kubernetes (the industry-standard system for managing containerized applications) all within the same platform. This is a significant differentiator: most competing solutions require separate infrastructure for each. Tintri’s patented technology observes each application individually and guarantees real-time resource delivery, even when the system is under heavy load. This eliminates the “noisy neighbor” problem, where resource-intensive applications steal resources and slow down everything else.

Why It Matters

Many companies today have AI running in multiple locations, either in a central data center, as well as out in the field on cameras, sensors, or other devices. Managing all of that separately is complex and expensive. This new platform unifies the entire setup under one management system (provided by Platform9), so IT teams spend less time juggling tools and more time moving their business forward.

Available now through Tintri’s global network of authorized partners, Phil Trickovic, Senior Vice President of Tintri said:“This launch represents a major milestone in our commitment to providing intelligent, autonomous infrastructure. We’re giving customers the exact tools they need to conquer the complexities of modern AI and edge computing, all while driving down operational costs.”

Hashtag: #Tintri #Platform9

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/tintri-and-platform9-announce-joint-solution-for-containerized-and-hypervisor-based-workloads/

Posted on

Strong Growth Prospects For European in Singapore’s Food Evolution

Source: Media Outreach

European Beef continues to grow in popularity in Singapore and is becoming one of the most sought-after products among consumers in the Asian country

SINGAPORE – Media OutReach Newswire – 25 March 2026 – In November 2025, Singapore adjusted its food security strategy, moving away from its “30 by 30” self-sufficiency target. This shift emphasizes global sourcing and strategic partnerships, creating an interesting opportunity for high-quality imports, including European beef from Spain.

Singapore’s shift towards a diversified and resilient food supply system underscores the importance of reliable imports. As Singapore improves its food security strategy, it also meets the growing demands of its sophisticated food scene, which highly values premium ingredients such as European beef.

The reason why European beef is the perfect choice.
Premium European beef is renowned for its exceptional flavor, while meeting the highest standards of safety, sustainability, traceability, and quality, in line with the European production model.

This makes it the perfect choice for the growing demand for high-quality meat in Singapore. As Singaporean diners increasingly seek unique experiences with premium beef, European beef offers a superior option, perfectly suited for fine dining restaurants and premium steakhouses, It is highly prized for its excellent qualities, such as its natural flavour, premium meat and superb texture.

With Singapore’s focus on diverse food sourcing, demand for high-quality beef is on the rise. The policy shift opens the door for European beef to flourish, especially in restaurants and food outlets that prioritize quality, taste, and sustainability.

European beef continues to grow in popularity in Singapore and is becoming one of the most sought-after products among consumers in the Asian country.

As Singapore strengthens its global food network, European beef is poised to become one of the preferred choices in the local market. The growing demand for sustainable, premium beef offers a significant opportunity for European beef to thrive in Singapore’s dynamic culinary landscape.

‘It’s time for European Beef in Singapore’.

Hashtag: #EuropeanBeef

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/strong-growth-prospects-for-european-in-singapores-food-evolution/

Posted on

Approaching.ai Brings in Top Scientists to Capture AI’s Inference Boom

Source: Media Outreach

BEIJING, CHINA – Media OutReach Newswire – 25 March 2026 – Approaching.ai has announced the appointment of two leading figures in computer science to accelerate its growth in high-efficiency AI infrastructure. Academician Wei-Min Zheng has joined as Chief Scientific Advisor, and Professor Yongwei Wu has been appointed Chief Scientist.

This move strengthens the company’s technical leadership and reinforces its long-term competitive moat in AI inference and Token production.

World-Class Expertise Reinforcing Technical Moat

Academician Wei-Min Zheng is a globally recognized authority in high-performance computing, distributed systems, and AI. His work on scalable storage architectures and parallel systems has had significant academic and industrial impact, earning multiple national science and technology awards.

Professor Yongwei Wu, an IEEE Fellow and AAIA Fellow, is an internationally recognized expert in parallel and distributed systems, cloud storage, and big data infrastructure, with multiple prestigious awards.

Their addition significantly enhances Approaching.ai’s ability to drive system-level innovation in large-scale AI inference—an area increasingly viewed as the core value layer of the AI industry.

Capturing the Core Value Layer: Inference and Token Production

As large models scale globally, demand for AI Tokens is growing exponentially. Inference is rapidly becoming the primary cost center and a key determinant of commercial viability.

Approaching.ai focuses on high-efficiency AI Token production, improving Token output per unit of compute and reducing deployment costs for enterprises.

Through system-level innovation, the company addresses key industry challenges:

  1. Fragmented computing resources
  2. Low inference efficiency
  3. Lack of standardized infrastructure

Its technologies—such as heterogeneous computing coordination and memory-compute optimization—enable unified execution across diverse hardware and models, creating a scalable and cost-efficient inference layer.

Strong Origin and Execution Capability

Originating from Tsinghua University’s High-Performance Computing Institute, Approaching.ai brings over 20 years of expertise in computing and storage systems, along with proven capability in translating research into industrial deployment.

Capital Validation and Market Confidence

Approaching.ai has attracted strong backing from leading venture capital firms and strategic investors, including GL Ventures, Verity Ventures, Shanghai Guofang Innovation Private Equity Fund Partnership (Limited Partnership), Xinglian Capital, Shangshi Capital, Tsinghua Capital, and other industry partners.

This reflects strong market confidence in the company’s positioning within the rapidly growing AI infrastructure market, particularly in inference optimization.

Looking Ahead

With strengthened scientific leadership, Approaching.ai will continue advancing enterprise-grade inference solutions and scalable AI infrastructure.

By focusing on Token production, the company targets one of the highest-leverage segments in the AI value chain and is well positioned to benefit from continued growth in AI adoption.

Hashtag: #AI

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/25/approaching-ai-brings-in-top-scientists-to-capture-ais-inference-boom/

Posted on

Save the Children Hong Kong’s “Heart to Heart Parent-Child Programme” Helps Parents Build Warmth and Boundaries for Children

Source: Media Outreach

From Authority to Companion: The Positive Parenting Journey of First-time Parents

HONG KONG SAR – Media OutReach Newswire – 25 March 2026 – For many families in Hong Kong, parenting can feel like a constant tug‑of‑war between time, stress and emotions. The Heart to Heart Parent‑Child Programme of Save the Children Hong Kong is a parent and child support programme that aims to help parents build confidence and skills in practising positive parenting and non‑violent communication, enabling children to feel respected, develop awareness of self‑protection, and strengthen parent‑child and family relationships.

The couple hopes to learn positive parenting through the programme, fostering a family relationship built on mutual respect.

Watch video interview: https://savethechildren.click/H2H_AppleCheukStory_PR

With demanding work commitments, parents often strive to provide for their children materially yet may lack the time or energy to truly understand one another’s feelings — which can strain family relationships.For Cheuk and Apple, parents of a four‑year‑old boy, becoming mum and dad gradually made them realise how deeply their own childhood experiences — growing up under scolding, pressure and emotional suppression, have shaped the way they now interact with their son. “In the past, whenever a problem came up, my first instinct was always to fix it straight away,” Cheuk recalled. Influenced by his upbringing, Cheuk often tackled conflicts by issuing instructions or letting emotions take charge, sometimes overlooking how his child or partner might feel in the moment. Apple shares that a lack of understanding and emotional support in her own childhood also affected how relationships are formed later in life. “I didn’t want to repeat that same pattern,” Apple explains. This reflection motivated the couple to join Save the Children Hong Kong’s Heart to Heart Parent‑Child Programme, breaking the cycle of traditional punitive discipline.

Building Loving Family and Daily Routine: Learning to Parent, Rediscovering Oneself

The Heart to Heart Parent‑Child Programme is a parent and child support programme based on Save the Children’s child protection framework, which has been implemented in over 40 countries worldwide. Adapted for Hong Kong, the programme has so far served more than 700 parents and caregivers and over 1,000 children. It aims to help parents build confidence and skills in practising positive parenting and non‑violent communication, enabling children to feel respected, develop awareness of self‑protection, and strengthen parent‑child and family relationships.

Programme facilitator Janet notes that many parents genuinely value their relationship with their children—”they want to do well but don’t know how”. Under heavy social and work pressure, it is easy for parents to fall back on familiar but unhealthy forms of discipline.

“Positive parenting does not mean spoiling.” Janet explained that the approach emphasises both family warmth and guidance with structure, which means acknowledging children’s emotions and needs, while also setting clear and safe boundaries. This helps children feel understood and, at the same time, learn appropriate behaviour and social norms.

Facilitator Janet explains that the programme emphasises both “family warmth” and “guidance with structure”.

In the parent group, Cheuk and Apple were introduced to many new concepts, such as “address feelings first, then deal with the problem” and the “Iceberg Theory” for identifying the underlying causes behind emotional outbursts. These concepts, which at first seemed abstract, gradually became practical and actionable through the four‑session parent workshop combining discussions and real‑life examples.

Parallel Learning for Parents and Children: Helping Children Put Emotions into Words

Parents are introduced to practical tools in the programme to help children recognise and express their feelings. One of these tools is the use of picture books and art activities.

“Colours and drawings can be a language for children,” Janet shared. Through picture books, parents and children can build a shared emotional language. For example, using colours to describe anger, calmness, or uneasiness helps children articulate their feelings more easily.

Apple shared that picture books and drawing created new opportunities for conversation. Even though her son is still young, “when we really sit down and listen, he does express himself.” The programme also includes parallel groups for children aged 6–12, allowing parents and children to learn positive communication together.

The children’s group uses picture books and art activities as tools to teach children to recognise and express emotions.

A small episode during the interview at the park perfectly illustrated how the family practises positive parenting. When their son had a tantrum after struggling with a drawing, Apple did not scold him and said calmly instead, “We wouldn’t know unless you teach us,” and expressed her feelings by saying, “When I see you losing your temper, I feel really upset.”

By expressing emotion from Apple’s own perspective, her son calmed down, shared what he needed, and with Cheuk’s help, the family continued enjoying their time together. Janet praised the couple’s patience. “They communicate honestly and share their feelings. These are the important elements in positive parenting.”

Apple and Cheuk patiently listened during their son’s emotional outburst, successfully soothing him and understanding his needs.

A Hug Speaks Louder Than Words: Positive Communication Strengthens Family Bonds

After learning positive parenting, they found that it not only improved their relationship with their son, but also strengthened their relationship as a couple. “Whether it’s with my child or my wife, paying attention to their emotions is so important,” Cheuk reflected. “Before, I just wanted to fix problems, but now I understand that sometimes the best response is simply a hug.”

For the couple, parenting is no longer just about “discipline” but a shared journey of companionship.

Apple said the mother and son now relate to each other as companions, supporting and growing alongside one another. “We’re not trying to raise a child who fits some standard answer,” Apple says. “We want him to be someone who can feel love, understand himself, and respect others.” That wish perfectly embodies the core spirit of Heart to Heart Programme.

For Apple and Cheuk, parenting is no longer just about discipline, but about becoming companions on a shared journey of growth.

Kalina Tsang, CEO of Save the Children Hong Kong, expressed her delight in witnessing Apple and Cheuk’s change:

“We are seeing more and more parents realise the importance of non‑violent communication and positive parenting. This not only improves parent‑child relationships but also effectively reduces emotional outbursts and the risk of escalating conflict. These changes are an essential first step in preventing child abuse.

With the implementation of the Mandatory Reporting of Child Abuse Ordinance, an important safety net is now in place for children. Yet this is only the starting point, not the end. We must also focus on prevention and education, helping families reduce risks before problems arise. Save the Children Hong Kong holds an uncompromising belief in non‑violent, positive parenting as the most effective approach to prevention.

Protecting children is a responsibility shared by the whole community, and we will continue to support Hong Kong families to ensure that every child grows up in safety, with respect and love.”

https://savethechildren.org.hk/en/
https://www.facebook.com/savethechildrenhk
https://www.instagram.com/savethechildrenhk/
YouTube: https://www.youtube.com/user/savehk

Hashtag: #SavetheChildrenHongKong #香港救助兒童會 #positiveparenting #正向管教 #childprotection #保護兒童

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/25/save-the-children-hong-kongs-heart-to-heart-parent-child-programme-helps-parents-build-warmth-and-boundaries-for-children/

Posted on

Ananda Launches Relocation Platform, Positioning Thailand as Asia’s Preferred Base for Global Living

Source: Media Outreach

‘One-Stop-Service’ Platform for Families and Investors Seeking Stability and Opportunity throughout Southeast Asia

BANGKOK, THAILAND – Media OutReach Newswire – 25 March 2026 – In response to growing geopolitical uncertainty, Ananda Development, a publicly listed Thai company and leading developer of urban residences including the landmark Porsche Design Tower Bangkok, today announced the launch of Ananda Relocation Services. This comprehensive, integrated platform is designed to provide a secure, stable, and luxurious base in Thailand for international families, professionals, and investors seeking peace of mind and long-term resilience.

Ananda Relocation Services

A Fully Integrated, One-Stop Solution

Ananda Relocation Services is designed as a fully integrated ecosystem to eliminate the complexities of moving abroad. Through a single point of contact, the platform provides coordinated access to a comprehensive range of services, including private jet transfer arrangements, private banking and wealth management coordination, access to leading international schools, and world-class healthcare services.

The platform provides a wide array of residency solutions, from premium serviced residences for short- to mid-term stays through leading operators such as La Clef, Ascott, and Somerset, to long-term home ownership opportunities. These range from condominiums near Bangkok’s mass transit network to luxury housing and high-end villas in Phuket. Notably, the program offers one-year long-term visa support for property purchases starting from THB 3,000,000 (Approx. $9x,xxx USD), creating a clear and simple path to residency.

Bangkok as a Thriving Global Hub

Bangkok has firmly established itself as one of Asia’s most attractive cities and a preferred destination for global citizens. The city is a vibrant hub of opportunity, offering unparalleled global connectivity that makes it a strategic second base. Its unique appeal lies in a dynamic blend of rich global cultures and a famously welcoming atmosphere that draws residents into a city full of life.

The city’s world-class infrastructure—including its robust banking sector, leading international schools, and premier healthcare systems—is a key factor that increasingly attracts global professionals, investors, and families seeking a new base. Ananda Relocation Services is designed to manage and facilitate every detail of the process to ensure a smooth transition, offering a truly seamless experience. While Bangkok serves as the primary gateway, the service also creates opportunities in other world-renowned destinations in Thailand.

Mr. Chanond Ruangkritya, Chief Executive Officer of Ananda Development, stated, “Bangkok has all the right fundamentals to become one of Asia’s most welcoming and strategic bases for international residents. Our relocation platform is designed to offer genuine peace of mind during a complex time with a seamless, worry-free transition experience for families and investors. By integrating residences, mobility, healthcare, education, and lifestyle services, we enable global citizens to establish themselves in Bangkok with confidence.”

He added, “This initiative aligns with Thailand’s increasing relevance in the global mobility landscape, as more individuals seek destinations that offer resilience, openness, and long-term livability.”

For individuals and families interested in relocating to Thailand or exploring residence and lifestyle opportunities with Ananda, please contact:

Ananda Relocation Services

Tel: +66 2 316 2222
WhatsApp: +66 81 720 3947
Email: relocation@ananda.co.th
Website: www.ananda.co.th

Hashtag: #Ananda

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/25/ananda-launches-relocation-platform-positioning-thailand-as-asias-preferred-base-for-global-living/

Posted on

DITP Hosts Thai Night Hong Kong 2026 to Strengthen Thailand’s Entertainment Industry Networks with Global Partners

Source: Media Outreach

HONG KONG SAR – Media OutReach Newswire – 25 March 2026 – The Department of International Trade Promotion (DITP), Ministry of Commerce, successfully hosted “Thai Night Hong Kong 2026” on 18 March 2026 at the Ballroom, JW Marriott Hong Kong, Hong Kong Special Administrative Region of the People’s Republic of China. The event aimed to foster business networking and promote collaboration between Thai entrepreneurs and international partners in the film and entertainment industry, with over 517 participants from across the global entertainment sector, including investors, content creators, and media representatives.

The event was graciously presided over by Her Royal Highness Princess Ubolratana Rajakanya Sirivadhana Barnavadi, who continues to play a vital role in supporting and promoting Thailand’s film and entertainment industry on the global stage. The occasion also provided a valuable platform for Thai entrepreneurs to expand business opportunities and strengthen international partnerships.

Thai Night Hong Kong 2026 was held alongside the Hong Kong International Film & TV Market (FILMART) 2026, one of Asia’s leading marketplaces for film and television content. The event served as a platform to celebrate the achievements of Thailand’s entertainment industry while showcasing the capabilities of Thai content creators to global buyers, investors, and industry stakeholders.

This year’s event was presented under the theme “Reimagining Thailand”, highlighting Thailand as a comprehensive creative destination for film and entertainment production. The concept reflects the country’s strengths in skilled talent, diverse filming locations, internationally recognized production standards, and advanced post-production capabilities.

The atmosphere of the event was vibrant and dynamic, with participants from various countries engaging in discussions, exchanging insights, and exploring opportunities for co-production and investment within Thailand’s entertainment sector.

In addition, the event featured live performances by Thai entertainment industry players, demonstrating the creativity and production excellence of Thai content. These performances blended contemporary storytelling with cultural identity, leaving a strong impression on international attendees and reinforcing Thailand’s position as a compelling creative partner on the global stage.

The successful organization of Thai Night Hong Kong 2026 reflects growing international interest in Thailand’s entertainment industry and underscores its potential as a key player in the global content landscape. The event also served as an important platform for Thai entrepreneurs to expand their market reach and build sustainable partnerships with international stakeholders.

Hashtag: #DITP

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/25/ditp-hosts-thai-night-hong-kong-2026-to-strengthen-thailands-entertainment-industry-networks-with-global-partners/

Posted on

SenseTime Group Reports Record High Revenue of Over RMB 5 billion in 2025; Second Half EBITDA Turns Positive

Source: Media Outreach

HONG KONG SAR – Media OutReach Newswire – 25 March 2026 – SenseTime (the “Company”; Stock Code: 0020) announced its annual results for 2025. For the full year, total revenue rose 33% year-on-year to more than RMB 5 billion, reaching a new record high and marking the fastest growth in three years. Net loss narrowed by 58.6% year-on-year, while adjusted net loss declined for a fourth consecutive half‑year period, with the pace of year‑on‑year reduction accelerating. EBITDA for the second half of 2025 reached RMB 380 million, turning positive for the first time since listing.

The Company has successfully transitioned from a technological investment phase into a period of sustainable and accelerated growth. During the reporting period, its endogenous growth momentum continued to strengthen, alongside improved capital efficiency and resilient cash flow generation. Trade receivables collection rose to a record RMB 4.87 billion. Operating cash flow recorded a positive net inflow in the second half of 2025, marking the first such achievement since listing.

Looking ahead, the Company plans to launch a new foundational model based on its second-generation NEO architecture in the second quarter of this year. The model is expected to deliver a further step in efficiency and cost-effectiveness, enabling the broad deployment of agentic AI applications.

Dr. Xu Li, Chairman of the Board and Chief Executive Officer of SenseTime, said: “We firmly believe that the deep integration of language and vision represents the most effective path to pushing the boundaries of artificial intelligence. Built on our innovative NEO architecture, we have achieved unified understanding and generation, while exploring a new ‘Scaling Law’ for multimodal intelligence. These technological breakthroughs, together with the deep integration of agentic AI, will unlock new application possibilities and enable a new generation of vertical use cases. While continuing to drive innovation in core technologies, SenseTime has delivered dual growth in both revenue and EBITDA, demonstrating strong growth resilience and operational efficiency across the industry, and is steadily advancing towards high-quality development.”

Continuously rolling out native multimodal large models, “efficiency enhancement + cost reduction” drives accelerated commercial growth

In 2025, SenseTime continued to invest in cutting-edge R&D, delivering breakthrough progress across large-model architecture innovation, training paradigms, inference efficiency, and spatial understanding, while maintaining its leading position in China.

The performance of the SenseNova multimodal large model continues to improve steadily, maintaining long-term leadership across multiple authoritative benchmarks. The Company has successively released and open-sourced the SenseNova-SI Spatial Intelligence Model. In a comprehensive evaluation incorporating several internationally recognized spatial intelligence benchmarks, SenseNova-SI delivered outstanding results, ranking first globally among peer models. In parallel, the open-source Kairos-SenseNova became the first embodied native world model to achieve integrated multimodal understanding, generation, and prediction. In December 2025, SenseTime also unveiled and open-sourced NEO, an fundamentally new native multimodal model architecture. NEO achieves state-of-the-art performance comparable to industry peers of a similar scale while requiring only one-tenth of the training data and computing power. Together, these breakthroughs redefined model training paradigms and inference efficiency, marking SenseTime’s entry into a new phase in its pursuit of deep multimodal integration

Leveraging the leading capabilities of its SenseNova multimodal large model, SenseTime has established a robust, scalable and replicable B2B business model. By applying a comprehensive framework that assesses task complexity and fault tolerance, the Company is able to unlock the closed-loop value of AI agents across strategic use cases, including office productivity, finance, marketing, and content generation. Its customer base spans a broad range of industries, encompassing automotive, smart devices, consumer goods, Internet services, embodied intelligence, financial services, education and healthcare.

Meanwhile, SenseTime has continued to make progress in developing a new generation of AI-native consumer applications. The Kapi product series has successfully built a user base numbering in the tens of millions, underscoring the strong growth potential of AI-native applications and demonstrating the Company’s ability to embed advanced AI technologies into everyday life.

SenseCore: Deeper coordination between computing infrastructure and model R&D unlocks international commercial potential

As the core technological pillar of its “Infrastructure – Model – Application” strategy, SenseCore achieved a significant transition in 2025, converting technological strengths to a fully developed industrial closed loop. During the year, it supported nearly one million model R&D tasks, effectively unlocking the full chain from underlying hardware to top-level applications, and from software stacks to model adaptation. Notably, the LightX2V World Model Inference System delivered breakthrough performance on domestic hardware, outperforming leading overseas chips.

SenseCore accelerated collaboration across China’s domestic technology ecosystem, positioning itself as a key chain master within industry. It partnered with more than a dozen chip makers, including Huawei Ascend, Hygon and Cambricon, to launch the SenseCore Computing Power Mall. SenseCore has since become a core partner of leading research institutes, Internet giants, pan-entertainment groups, embodied-intelligence robotics firms and large-model unicorns, and has also launched China’s first overseas Chinese-led computing cluster in Saudi Arabia.

As of the release of this result announcement, the total operational computing scale of SenseCore had reached 40,400 PetaFLOPS (FP16).

CV 2.0 records first‑ever net profit and positive cash flow; “X” Businesses gains strong recognition from external investors

SenseTime’s Computer Vision (CV; Visual AI) business is transitioning from a technology investment phase into a period of large-scale commercial returns. During the reporting period, CV 2.0 achieved profitability for the first time and generated positive cash flow for a second consecutive year, emerging as a key driver of the Company’s revenue growth and cash-flow improvement. SenseTime has maintained the leading position in China’s CV market for nine consecutive years. Internationally, clients across Southeast Asia, Northeast Asia and the Middle East continued to repurchase CV products and services, while interest increased from clients in South America, Europe and other regions, forming a replicable, scalable “Chinnovation” model for global expansion.

In 2025, SenseTime firmly advanced its “1+X” strategy, establishing a highly efficient collaborative system in which the core platform (the Company) provides foundational capabilities, while ecosystem partners compete and scale within targeted verticals. This marked a strategic shift from standalone business expansion towards the multiplication of ecosystem-wide value. Ecosystem enterprises incubated by SenseTime made steady progress in financing during the year, attracting strong interest from external investors including Internet giants, leading venture capital firms and industrial funds. Notably, the edge AI chip and intelligent driving business successfully completed financing rounds and were subsequently spun off to operate independently.

Looking ahead to 2026, the Company believes it is well positioned to compete in the critical phase of the global AI industry. It will continue to deepen its native multimodal architecture, reinforcing its global leadership in the integration of native multimodal large models and spatial intelligence. Meanwhile, the Company plans to capitalize on opportunities in the merging agentic AI market, targeting rapid growth in both user scale and commercial value. The Company will also accelerate the adaptation of domestic Chinese chips, further reduce large-model inference costs, and enhance product competitiveness through superior cost-performance. Within its Visual AI business, it will leverage both domestic and international growth engines to drive large-scale expansion and establish a global benchmark for intelligent industries. In parallel, the Company will continue to advance its “1+X” strategy to capture incremental returns arising from the accelerating intelligent transformation of vertical industries.

Hashtag: #SenseTimeGroup

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/25/sensetime-group-reports-record-high-revenue-of-over-rmb-5-billion-in-2025-second-half-ebitda-turns-positive/

Posted on

TrendAI™ Secures the OpenClaw-Driven AI Era

Source: Media Outreach

Introducing new security solution designed for the rapidly emerging era of agentic AI

HONG KONG SAR – Media OutReach Newswire – 25 March 2026 – TrendAI , the enterprise AI security leader, today introduced TrendAI Agentic Governance Gateway, a new security solution engineered to give organizations visibility and control over autonomous agent interactions to strengthen security where systems interact across data, tools, and environments with increasing autonomy.

To learn more about TrendAI and TrendAI Agentic Governance Gateway, visit: trendaisecurity.com.

Rachel Jin, CPBO and Head of TrendAI : “Tools like OpenClaw show just how powerful and accessible this new model has become. Organizations need to deploy these systems to unlock the next wave of productivity, and many already are, often without centralized oversight. TrendAI Agentic Governance Gateway enables this by providing visibility, control, and confidence.”

Traditional cybersecurity is built to protect endpoints, networks, and applications. In contrast, agentic AI systems operate across dynamic chains of interaction where agents, models, APIs, and data continuously exchange information and trigger actions.

Eva Chen, CEO of Trend Micro: “As AI systems become more autonomous, security must evolve from protection to governance. This is the next frontier of cybersecurity and the focus of TrendAI .”

TrendAI Agentic Governance Gateway is a new way to address the emerging security gap created by agentic AI systems, such as OpenClaw, where autonomous agents act across enterprise environments without clear security control points. This was demonstrated last week at NVIDIA GTC, where a fundamentally new attack surface was highlighted – one that traditional security models were not designed to control: Autonomous agentic frameworks, such as OpenClaw, accelerating enterprise adoption of AI systems capable of planning, executing, and coordinating actions across workflows at machine-speed. There has never been a more critical business-level need than understanding and governing how agentic systems behave, and what actions they are taking. The orchestration required to monitor this attack surface created complex, multi-step workflows across enterprise systems until now.

According to Forrester, “AI agents are proliferating across workflows, but security programs built for human-centric architectures fail in agentic environments. These agents operate with dynamic reasoning, ephemeral identities, and goal-driven autonomy, creating unpredictable attack paths. Risks to agentic architectures include intent hijacking and cascading hallucinations that extend beyond confidentiality to integrity and availability. Without guardrails, enterprises risk regulatory violations, financial loss, and disclosure events from agentic security issues.” 1

TrendAI ’s Agentic Governance Gateway allows enterprises to focus on the behavior, interactions, and outcomes of AI systems in real-world environments. TrendAI Agentic Governance Gateway is delivered through the TrendAI Vision One platform, building on TrendAI ’s existing strengths, including AI-driven analytics to detect anomalous behavior and emerging threats, and a unified approach that correlates context across endpoints, cloud, applications, and AI systems.

TrendAI ’s Agentic Governance Gateway enables enterprises to:

  • Gain visibility into how agents interact across systems
  • Understand the context and intent behind agent communications to identify risky or unintended actions
  • Enforce policy and control over agent-driven actions
  • Introduce human oversight at critical decision points
  • Simulate governance decisions before deployment — previewing the full policy impact without executing it
  • Stage, preview, and roll back governance changes through a managed lifecycle

With these new advanced capabilities, TrendAI is enabling organizations to secure the critical interaction layer – the dynamic communication fabric where autonomous systems coordinate, make decisions, and drive enterprise actions. By establishing robust oversight and control at this pivotal layer, TrendAI ensures that agentic interactions are visible, governed, and trusted, effectively closing the security gap in agent-driven AI environments.

TrendAI is the enterprise business unit of Trend Micro Incorporated (TYO: 4704; TSE: 4704).

1: The AEGIS Agent-On-A-Page Template For Agentic Security, Forrester Research, Inc., Feb 13, 2026.

https://www.trendaisecurity.com
https://www.linkedin.com/company/trendai-security
https://x.com/trendaisecurity
https://www.facebook.com/trendaisecurity/
https://www.instagram.com/trendaisecurity/

Hashtag: #trendai #trendmicro #trendvisionone #trendaivisionone #visionone #cybersecurity

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/25/trendai-secures-the-openclaw-driven-ai-era/

Posted on

Natural Diamonds Dazzle on The Red Carpet at The 98th Academy Awards

Source: Media Outreach

Today’s biggest stars express individuality and confidence with natural diamonds

LOS ANGELES, US – Media OutReach Newswire – 25 March 2026 – The 98th annual Academy Awards took place March 15th at the Dolby Theatre in Los Angeles, California, effectively ending awards season with an unforgettable evening. The most notable actors in the world showcased the most classic, refined and distinctive diamond jewelry looks of the season. Below, we highlight the standout trends from the event.

From left to right: Chase Infiniti, Rose Byrne, Keltie Knight, Barbie Ferreira (Photo Credits: Getty Images)

Desert diamonds

Once again Desert diamonds were front and center, further confirming it as the standout diamond trend of the season. Rose Byrne wore the most important diamond high jewelry of the year in a sculptural torque necklace featuring a 22.58 carat fancy yellow-brown pear-shaped Desert diamond, and an Arizona Blue ceramic and 18k rose gold ring centering a 16.54 Ashoka-cut diamond sourced from Botswana, both one-of-a-kind pieces by legendary design house TAFFIN. Chase Infiniti wore the ‘Summer’ Choker Necklace from De Beers London’s Metamorphosis 2023 Couture Collection, featuring a fancy intense yellow cushion diamond at its center; Drops of Light fancy vivid yellow pear-shaped diamond jacket earrings; and Aura fancy yellow cushion-cut Diamond Line Bracelet all by De Beers London. Barbie Ferreira wore the Arpeggia Three Line Diamond Necklace with varying shades of sunlit white and yellow diamonds, and Talisman Chandelier Diamond Earrings featuring yellow rough diamonds and white polished diamonds, both from De Beers London. Keltie Knight wore fancy intense yellow Asscher-cut diamond drop earrings , a fancy yellow radiant-cut diamond ring, and a smoky yellow-brown diamond ring, all by Premier Gem.

Closely cropped necklaces

Closely cropped diamond necklaces in the form of torques, chokers and collars emerged as a defining styling choice, framing the neckline with brilliance and sculptural elegance. Jessie Buckley embraced the trend in a closely cropped diamond necklace by Chanel, while Elle Fanning selected a striking collar-style design by Cartier shaped like cascading wisteria, blending nature-inspired artistry with high jewelry craftsmanship. Kylie Jenner opted for a bold interpretation with an oversized diamond cluster necklace by Lorraine Schwartz, delivering maximum impact through scale and sparkle, while Arden Cho wore a stunning choker in the shape of feathers by Messika. Kate Hudson also leaned into the silhouette with a collar necklace by Garatti High Jewelry, reinforcing the growing prominence of diamond pieces worn close to the collarbone.

Diamond Brooches

Brooches made a confident return to the red carpet, emerging as one of the evening’s most expressive accessories. Hudson Williams, among the first actors to arrive, helped set the tone in a sparkling brooch by BVLGARI. Jeremy Pope embraced the trend with multiple brooches by Anabela Chan Jewelry, while Damson Idris wore a custom piece from his own brand, DIDRIS. The styling momentum of sparkling diamonds against black tie continued across the carpet, with Fortune Feimster, Milo Manheim, Kumail Nanjiani, Joe Alwyn, Kieran Culkin, Wagner Moura, and Raphael Saadiq all incorporating brooches into their looks. Channing Tatum and Shaboozey also participated in the diamond brooch trend, with Shaboozey notably wearing two brooches, including one styled as a neck closure, highlighting the accessory’s renewed versatility and modern appeal.

https://www.debeersgroup.com/
https://www.linkedin.com/company/debeersgroup/posts/?feedView=all
https://www.facebook.com/DeBeersGroupOfCompanies
https://www.instagram.com/debeersgroup/

Hashtag: #adiamondisforever #naturaldiamonds #diamonds #Desertdiamonds #VanityFair #Oscars

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/25/natural-diamonds-dazzle-on-the-red-carpet-at-the-98th-academy-awards/

Posted on

Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes

Source: Media Outreach

  • UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk
  • In a phase 2 trial in Chinese people with type 2 diabetes, UBT251 showed a mean HbA1c reduction of up to 2.16%, and a mean body weight reduction of up to 9.8% after 24 weeks, showing improvements relative to placebo and semaglutide 1 mg
  • The safety and tolerability profile of UBT251 appeared consistent with what has been observed in other clinical trials with triple-G agonists.

GAUNG DONG, CHINA and BAGSVÆRD, DENMARK – Media OutReach Newswire – 25 March 2026 – The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced topline results from a Chinese phase 2 trial of UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon (triple G).

UBT251 is being jointly developed by TUL’s wholly-owned subsidiary, The United Bio-Technology (Hengqin) Co., Ltd. (United Biotechnology) and Novo Nordisk under an agreement signed in March 2025. United Biotechnology is responsible for development in Chinese mainland, Hong Kong, Macau and Taiwan, while Novo Nordisk is responsible for development in the rest of the world.

The trial, conducted by United Biotechnology, investigated the safety and efficacy of once-weekly injectable 2 mg, 4 mg and 6 mg doses of UBT251 compared to placebo and semaglutide 1 mg in Chinese people with type 2 diabetes. From a baseline mean glycated haemoglobin (HbA1c) of 8.12%, the highest mean HbA1c reduction observed for people treated with UBT251 was 2.16% compared to 1.77% for the semaglutide 1 mg group and 0.66% for the placebo group after 24 weeks of treatment.

From a baseline mean body weight of 80.1 kg and a mean BMI of 29.1 kg/m², the mean body weight reduction in the UBT251 groups was up to 9.8% compared with 4.8% in the semaglutide 1 mg group and 1.4% in the placebo group1.

Moreover, UBT251 showed improvements relative to placebo on key secondary endpoints, including waist circumference, blood pressure and lipids. The safety and tolerability profile of UBT251 appeared consistent with what has been observed in other clinical trials with triple-G agonists.

“The success of the phase 2 trial for UBT251 in Chinese patients with type 2 diabetes marks a significant milestone in the innovative development of TUL,” remarked Mr Tsoi Hoi Shan, Chairman of TUL. “We will fully advance the phase 3 trial in China, committed to providing superior treatment options for patients worldwide.”

“Following the recent positive read-out of phase 2 data in people with overweight or obesity, we are encouraged to see the results of this trial, which also demonstrate the potential of UBT251 in a type 2 diabetes population,” said Martin Holst Lange, executive vice president, chief scientific officer and head of Research and Development at Novo Nordisk. “Novo Nordisk will initiate a global phase 2 trial with UBT251 in people with type 2 diabetes later this year, and we are already conducting a global phase 2 trial in weight management that will read out next year.”

Novo Nordisk’s recently initiated global phase 1b/2a trial is investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of different doses of UBT251 for up to 28 weeks in around 330 people living with overweight or obesity. Topline data from that trial is expected in 2027. Novo Nordisk expects to initiate the global phase 2 trial with UBT251 in people with type 2 diabetes in the second half of 2026.

United Biotechnology will present detailed data from the Chinese phase 2 trial at a medical congress later this year. Based on the results of this trial, the company is planning to initiate two phase 3 trials in Chinese patients with type 2 diabetes.

About the Chinese phase 2 trial

This randomised, double-blind, placebo- and semaglutide-controlled trial enrolled a total of 211 Chinese patients with type 2 diabetes (managed with lifestyle intervention alone or in combination with metformin). At baseline, the patients had a mean HbA1c of 8.12%, a mean body weight of 80.1 kg, and a mean body mass index (BMI) of 29.1 kg/m².

Patients were randomly assigned to receive weekly subcutaneous injections of UBT251 in doses of 2 mg, 4 mg, 6 mg or placebo, or semaglutide 1 mg for 24 weeks. The primary endpoint of the trial was the change in HbA1c from baseline after 24 weeks of treatment.

About UBT251

UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon.

In March 2025, United Biotechnology entered an exclusive license agreement with Novo Nordisk A/S for UBT251. Under the agreement, Novo Nordisk obtained exclusive worldwide rights (excluding Chinese mainland, Hong Kong, Macau, and Taiwan) to develop, manufacture and commercialise UBT251. United Biotechnology retained the rights for UBT251 in Chinese mainland, Hong Kong, Macau and Taiwan.

1 Estimated based on the analysis of covariance (ANCOVA) model; Based on the efficacy estimand according to the trial protocol, regardless of dose modification or changes to background metformin dose

Hashtag: #UBT251

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/25/triple-agonist-ubt251-showed-a-mean-hba1c-reduction-of-up-to-2-16-after-24-weeks-in-phase-2-trial-in-chinese-patients-with-type-2-diabetes/